1. The Stages of Reproductive Aging Workshop (STRAW) staging system, Fertility and Sterility 76:874-878, 2001
2. Faddy MJ, Gosden RG, Gougeon A: Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reproduction 1992; 7:1342-1346
3. Luoto R, Laprio J, Uutela A: Age at natural menopause and sociodemographic status in Finland. Am J Epidemiol 1994; 139:64-76
5. de Bruin JP, Bovenhuis H, van Noord P: The role of genetic factors in age at natural menopause. Hum Reprod 2001; 16:2014-2018
6. Kaufman DL, Slone D, Rosenberg L, Miettinen OS, Shapiro S: Cigarette smoking and age of natural menopause. American Journal of Public Health 70 (4): 420-422
7. Luborsky JL, Meyer P, Sowers MF, Gold EB, Santoro N: Premature menopause in a multi-ethnic population study of the menopause transition. Hum Reproduction 2003 Jan; 18(1):199-206.
8. Judd HL, Mebane-Sims I, Legault C, Wasilaskas C, Johnson S, Merino M: 1995 Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 273:199-208
9. Minino AM, Arias E, Kochanek KD, Murphy SL, Smith BL. Deaths: final data for 2000. Natl Vital Stat Rep 50(15):1-108
10. Kannel WB, Hjortland MC, McNamara PM, Gordon T.: Menopause and the risk of cardiovascular disease. The Framingham study. Ann Intern Med 1976; 85:447-452
11. Hulley S, Grady D, Bush T, Furber C, Herrington D, Riggs B, Vittinghoff E. 1998 Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605-613.
12. Matthews KA, Meilahn E, Kuller LH: Menopause and risk factors for coronary heart disease. N Engl J Med 1989; 321:641-646.
13. Stefanick ML, Mackey S, Sheehan M, Ellsworth N, Haskell WL, Wood PD. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. 1998 New Engl J Med Jul 2; 339(1):12-20
14. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertension 2003 Jun;21(6):1011-53
15. Manson JE et. al Estrogen plus progestin and the risk of coronary heart disease N Engl J Med. 2003 Aug 7;349(6):523-34
16. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogens in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; (291)1701-1712
17. Miller et al. Using Basic Science to Design a Clinical Trial: Baseline Characteristics of Women Enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res. 2009 Sep;2(3):228-239. Epub 2009 May 22
18. Manson JE et al Estrogen therapy and coronary-artery calcification N Engl J Med. 2007 Jun 21; 356(25):2591-602
19. Gilligan DM, Quyyumi AA, Cannon III RO: Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 1994; 89:2545-2551
20. Wu O. Postmenopausal hormone replacement therapy and venous thromboembolism Gend Med. 2005;2 Suppl A:S18-27
21. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. 1998 JAMA 279(18):1445-51
22. Bagdade JD, Wolter J, Subbaiah PV, Ryan W. 1990 Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition. J Clin Endocrinol Metab 70(4):1132-5
23. Cummings SR, Kelsey JL, Nevitt MC, O'Dowd KJ. 1985 Epidemiology of osteoporosis and osteoporotic fractures Epidemiol Rev 7:178-208
24. Riggs BL, Wahmer HW, Melton L., et al: Rates of bone loss in the appendicular and axial skeletons of women: evidence of substantial vertebral bone loss before menopause. J Clin Invest 1986; 77:1487-1491
25. Riggs BL: The mechanisms of estrogen regulation of bone resorption J Clin Invest 2000; 106:1203-1204
26. Ettinger B. 1988 Prevention of osteoporosis: treatment of estradiol deficiency. Obstet Gynecol 72 (5 supplem): 12S-17S
27. Shoback D, Marcus R, Bikle D, Strewler G. Greenspan FS and Gardner DG, eds. Mineral metabolism and bone disease. Basic & clinical endocrinology, 6th ed. pp. 310-8
28. The National Osteoporosis Foundation, http://www.nof.org/physguide/diagnosis.htm
29. Paganini-Hill A., Chao A., Ross R.K., Henderson B.E.: Exercise and other factors in the prevention of hip fracture: the leisure world study. Epidemiology 1991; 2:16-25
30. Puntila E, Kroger H, Lakka T, Tuppurainen M, Jurvelin J, Honkanen R. 2001 Leisure-time physical activity and rate of bone loss among peri- and postmenopausal women: a longitudinal study. Bone 29(5): 442-6
31. Dawson-Hughes B., Harris SS, Krall EA, Dalla GE: Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337:670-676
32. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK et al. 1999 Reduction in vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene JAMA 282(7): 637-645.
33. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA et al. 1999 The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 281: 2189-2197.
34. Eastell R, Hannon RA: Biochemical markers of bone turnover. In: Lobo R.A., ed. Treatment of the Postmenopausal Woman Basic and Clinical Aspects, 3rd ed. St. Louis: Elsevier Academic Press; 2007, p: 337-350
35. Cummings SR, Palermo L, Browner W, Marcus R, Wallace R, Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. JAMA 283(10): 1318-21
36. Col NF, Guthrie JR, Politi M, Dennerstein L. Duration of vasomotor symptoms in middle-aged women: a longitudinal study. Menopause 2009 May-Jun;16 (3):453-7
37. Meldrum DR, Tataryn IV, Frumar AM et al: Gonadotropins, estrogens, and adrenal steroids during the menopausal hot flash. J Clin Endocrinol Metab 1980; 50:685-689
38. Kimura D. 1995 Estrogen replacement therapy may protect against intellectual decline in postmenopausal women. Horm Behav 29:312-21
39. Shaywitz SE, Shaywitz BA, Pugh KR, Fulbright RK, Skudlarski P, Menck WE et al. 1999 Effects of estrogen on brain activation patterns in postmenopausal women during working memory tasks. JAMA 281(13):1197-1202
40. Shumaker SA, et al. Conjugated Equine Estrogen and Incidence of Probable Dementia and Mild Cognitive Impairment in Postmenopausal Women: Women's Health Initiative Memory Study. 2004 JAMA 291(24): 2947-58
41. Barrett-Connor E, Kritz-Silverstein D. 1993 Estrogen replacement therapy and cognitive function in older women. JAMA 269:2637-41
43. Manly JJ, Merchant CA, Jacobs DM, Small SA, Bell K, Ferin M et al. 2000 Endogenous estrogen levels and Alzheimer's disease among postmenopausal women. Neurology 54(7):833-7
44. Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A et al. 1997 A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore longitudinal study. Neurology 48(2):1517-21
45. Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B et al. 1996 Effects of oestrogen during menopause on risk and age of onset of Alzheimer's disease. Lancet 348: 429-32
46. Asthana S, Baker LD, Craft S, Stanczyk FZ, Veith RC, Raskind MA et al. 2001 High-dose estradiol improves cognition for women with AD: results of a randomized trial. Neurology 57(4):605-12
47. Henderson VM, Paganini-Hill A, Emanuel CK, Dunn ME, Buckwalter JG. Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects Arch Neurol 51(9):896-900
48. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R et al. 2000 Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease. JAMA 283(8): 1007-1015
49. Henderson VW, Paganini-Hill A, Miller BL, Elble RJ, Reyes PF, Shoupe D et al. 2000 Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology 54: 295-301
50. McEwen BS, Alves SE, Bulloch K, Weiland NG. 1997 Ovarian steroids and the brain: implications for cognition and aging. Neurology 48 (Supp 7): S8-15
51. Gandy S, Duff K. 2000 Post-menopausal estrogen deprivation and Alzheimer's disease. Exp Gerontol 35(4):503-11
52. Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women, The Women's Health Initiative Memory Study: A Randomized Controlled Trial JAMA. 2003;289:2651-2662
53. Lobo RA, Rosen RC, Yang HM, Block B, Van Der Hoop RG. 2002 Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil and Steril 79(6): 1341-52
54 Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP et al. 2000 Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. New Engl J Med 343 (10): 682-8
55. Buster JE, Kingsberg SA, Aguirre O, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 2005;105:944-952
56. Davis SR, et al. APHRODITE Study Team: Testosterone for low libido in postmenopausal women not taking estrogen.N Engl J Med. 2008 Nov 6;359(19):2005
57. Somboonporn W, Davis SR. Testosterone effects on the breast: implications for testosterone therapy for women. Endocr Rev 2004;25:374-388. [Free Full Text]
58. Hankinson SE, Eliassen AH. Endogenous estrogen, testosterone and progesterone levels in relation to breast cancer risk. J Steroid Biochem Mol Biol 2007;106:24-30
59. Sakorafas GH, Krespis E, Pavlakis G. 2002 Risk estimation for breast cancer development; a clinical perspective. Surg Oncol 10(4):183-192
60. Chlebowski R et al. Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women: The Women's Health Initiative Randomized Trial JAMA. 2003;289:3243-3253
61. Stefanick et al. Effects of Conjugated Equine Estrogens on Breast Cancer and Mammography Screening in Postmenopausal Women With Hysterectomy JAMA. 2006;295:1647-1657
62. Greendale GA, Reboussin BA, Sie A, Singh HR, Olson LK, Gatewood O et al. 1999 Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Ann Intern Med 130: 262-9
63. Crandall et al. Positive association between mammographic breast density and bone mineral density in the Postmenopausal Estrogen/Progestin Interventions Study. Breast Cancer Res. 2005; 7(6):R922-8. Epub 2005 Sep 22
64. Bonnier P, Romain S, Giacalone PL, Laffargue F, Martin PM, Piana L. 1995 Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 85(1):11-7
65. Delgado RC, Lubian Lopez DM. 2001 Prognosis of breast cancers detected in women receiving hormone replacement therapy. Maturitas 38(2):147-56
66. Spiegelman et al Validation of the Gail et al. model for predicting individual breast cancer risk. J Natl Cancer Inst. 1994 Apr 20;86(8):600-7
67. Fisher B, Costantino JP, Wickerham DL, Redmond CK , Kavanah M, Cronin WM et al. 1998 Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 90(18):1371-88
68. Vogel VG et al. Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial Journal of the American Medical Association 2006 Jun 21;295(23):2727-41
70. Guide to Clinical Preventive Services: Report of the U.S. Preventive Services Task Force. 2nd ed. Baltimore, Md: Williams & Wilkins; 1995
71. Leiblum S, Bachmann G, Kemmann E, Colburn D, Swartzman L. 1983 Vaginal atrophy in the postmenopausal woman. The importance of sexual activity and hormones JAMA 249(16): 2195-8.
72. Rioux JE, Devlin MC, Gelfand MM, Steinberg, Hepburn DS. 2000 17[beta]-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis Menopause; 7:156–61.
73. Hendrix et al. Effects of Estrogen With and Without Progestin on Urinary Incontinence JAMA. 2005;293:935-948
74. Henriksson L, Stjernquist M, Boquist L. 1996 A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol 174:85–92
75. Labrie F, Belanger A, Cusan L, Gomez J-L, Candas B. 1997 Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab 82:2396
76. NAMS Board of Trustees 2004 Treatment of menopause-associated vasomotor symptoms: position statement of the North American Menopause Society. Menopause: The journal of the NAMS 11(1): 11-33
77. Stearns V, Beebe KL, Iyengar M, Dube E. 2003 Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 289:2827-34
78. Loprinzi CL et al. Phase III evaluation of fluoxetine for treatment of hot flashes JClin Oncol. 2002 Mar 15;20 (6):1578-83
79. Loprinzi CL, Kugler JW, Sloan JA, et al. 2000 Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial. Lancet 356:2059-63.
80. Butt DA et al. Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial Menopause. 2008 Mar-Apr;15 (2):310-8.
81. Toulis KA et al. Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis Clin Ther. 2009 Feb;31(2):221-35
82. Judd HL, Mebane-Sims I, Legault C, Wasilaskas C, Johnson S, Merino M et al. 1996 Effects of hormone replacement therapy on endometrial histology in postmenopausal women. JAMA 275(5):370-5.
83. Ettinger B, Selby J, Citron JT, Vangessel A, Ettinger VM, Hendrickson MR. 1994 Cyclic hormone replacement therapy using quarterly progestin. Obstet Gynecol 83: 693-700.